The future of antibodies as cancer drugs

Drug Discovery Today

Volumn 17, Issue 17-18, 2012, Pages 954-963

  Reichert, Janice M ^a   Dhimolea, Eugen ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 80; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; BLINATUMOMAB; BRENTUXIMAB VEDOTIN; CALICHEAMICIN; CANCER ANTIBODY; CARBOHYDRATE; CD20 ANTIGEN; CETUGEX; CETUXIMAB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GA 201; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; ICRUCUMAB; INOTUZUMAB OZOGAMICIN; MM 151; MM 302; MOGAMULIZUMAB; MONOCLONAL ANTIBODY; NAPTUMOMAB ESTAFENATOX; NECITUMUMAB; NIMOTUZUMAB; OBINUTUZUMAB; OCARATUZUMAB; OFATUMUMAB; PANITUMUMAB; RAMUCIRUMAB; RG 7160; RG 7597; RITUXIMAB; RO 5083945; SYM 004; TANDABS; TOSITUMOMAB I 131; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UBLITUXIMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELTUZUMAB;

ANTIBODY ENGINEERING; CANCER IMMUNOTHERAPY; DRUG CONJUGATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; HYPERSENSITIVITY REACTION; NEOPLASM; NONHUMAN; REVIEW; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; T-LYMPHOCYTES;

EID: 84865455090     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.04.006     Document Type: Review

References (76)

1. G. Casi, and D. Neri Antibody-drug conjugates: basic concepts, examples and future perspectives J. Control. Release 2012 in press, corrected proof, available online 26 January
2. B.A. Teicher, and R.V. Chari Antibody conjugate therapeutics: challenges and potential Clin. Cancer Res. 17 2011 6389 6397
3. J.G. Jurcic What happened to anti-CD33 therapy for acute myeloid leukemia? Curr. Hematol. Malig. Rep. 7 2012 65 73
4. P. Sapra Investigational antibody drug conjugates for solid tumors Expert Opin. Investig. Drugs 20 2011 1131 1149
5. P.M. LoRusso Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer Clin. Cancer Res. 17 2011 6437 6447
6. A.D. Ricart Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin Clin. Cancer Res. 17 2011 6417 6427
7. S. Canevari Bispecific antibody targeted T cell therapy of ovarian cancer: clinical results and future directions J. Hematother. 4 1995 423 427
8. F.H. Valone Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu J. Clin. Oncol. 13 1995 2281 2292
9. D. Müller, and R.E. Kontermann Bispecific antibodies for cancer immunotherapy: current perspectives BioDrugs 24 2010 89 98
10. R. Linke Catumaxomab: clinical development and future directions MAbs 2 2010 129 136
11. R. Kontermann Dual targeting strategies with bispecific antibodies MAbs 4 2012 182 197
12. M.S. Topp Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival J. Clin. Oncol. 29 2011 2493 2498
13. P. Chames, and D. Baty Bispecific antibodies for cancer therapy: the light at the end of the tunnel? MAbs 1 2009 539 547
14. J. Zalevsky Enhanced antibody half-life improves in vivo activity Nat. Biotechnol. 28 2010 157 159
15. A. Okazaki Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa J. Mol. Biol. 336 2004 1239 1249 (Pubitemid 38229710)
16. T. Shinkawa The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity J. Biol. Chem. 278 2003 3466 3473 (Pubitemid 36801263)
17. E. Kaneko, and R. Niwa Optimizing therapeutic antibody function: progress with Fc domain engineering BioDrugs 25 2011 1 11
18. J.R. Desjarlais, and G.A. Lazar Modulation of antibody effector function Exp. Cell Res. 317 2011 1278 1285
19. S.A. Antoniu Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma Curr. Opin. Mol. Ther. 12 2010 770 779
20. T. Ishida Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter Phase II study J. Clin. Oncol. 30 2012 837 842
21. C. Owen, and D.A. Stewart Obinutuzumab for the treatment of lymphoproliferative disorders Expert Opin. Biol. Ther. 12 2012 343 351
22. A.L. Nelson, and J.M. Reichert Development trends for therapeutic antibody fragments Nat. Biotechnol. 27 2009 331 337
23. A.L. Nelson Antibody fragments: hope and hype MAbs 2 2010 77 83
24. G. Forsberg Naptumomab estafenatox, an engineered antibody-superantigen fusion protein with low toxicity and reduced antigenicity J. Immunother. 33 2010 492 499
25. H. Shim One target, different effects: a comparison of distinct therapeutic antibodies against the same targets Exp. Mol. Med. 43 2011 539 549
26. P. Seshacharyulu Targeting the EGFR signaling pathway in cancer therapy Expert Opin. Ther. Targets 16 2012 15 31
27. E.E. Vokes, and E. Chu Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers Oncology (Williston Park) 20 Suppl. 2 2006 15 25
28. A. Talavera Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation Cancer Res. 69 2009 5851 5859
29. M.S. Ramakrishnan Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin MAbs 1 2009 41 48
30. G.P. Kim, and A. Grothey Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab Biologics 2 2008 223 228
31. D.G. Allan Nimotuzumab: evidence of clinical benefit without rash Oncologist 10 2005 760 761 (Pubitemid 41567290)
32. T. Crombet Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients J. Clin. Oncol. 22 2004 1646 1654 (Pubitemid 41079803)
33. C.H. Chung Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose N. Engl. J. Med. 358 2008 1109 1117 (Pubitemid 351398485)
34. T. Schneider-Merck Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage J. Immunol. 184 2010 512 520
35. S. Li Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8 Structure 16 2008 216 227 (Pubitemid 351215209)
36. R. Dienstmann, and E. Felip Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development Expert Opin. Biol. Ther. 11 2011 1223 1231
37. A.M. Scott A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors Proc. Natl. Acad. Sci. U. S. A. 104 2007 4071 4076 (Pubitemid 47181580)
38. B. Markman Phase I PK/PD study of RO5083945 (GA201), the first glycoengineered anti-EGFR monoclonal antibody (mAb) with optimized antibody dependent cellular cytotoxicity (ADCC) J. Clin. Oncol. 28 2010 15s (Suppl. Abstr. 2522)
39. L.G. Paz-Ares Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors J. Clin. Oncol. 29 2011 3783 3790
40. Glycotope GmbH (http://www.glycotope.com/pipeline/cetugex )
41. K. Koefoed Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor MAbs 3 2011 584 595
42. M.W. Pedersen Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy Cancer Res. 70 2010 588 597
43. ® Pharmaceuticals (http://www.merrimackpharma. com/pipeline/mm-151/ )
44. G. Schaefer A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies Cancer Cell 20 2011 472 486
45. A.V. Kamath Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose Cancer Chemother. Pharmacol. 69 2011 1063 1069
46. F.R. Hirsch Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer Oncogene 28 Suppl. 1 2009 32 37
47. M.C. Franklin Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex Cancer Cell 5 2004 317 328 (Pubitemid 38482068)
48. N.G. Schaefer Radioimmunotherapy in non-Hodgkin lymphoma: opinions of nuclear medicine physicians and radiation oncologists J. Nucl. Med. 52 2011 830 838
49. Zevalin prescribing information. Available at: http://www.accessdata.fda. gov/drugsatfda-docs/label/2011/125019s0194lbl.pdf (accessed 19.4.2012)
50. Bexxar prescribing information. Available at: http://www.accessdata.fda. gov/drugsatfda-docs/label/2004/125011-0024lbl.pdf (accessed 19.4.2012)
51. J.L. Teeling The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20 J. Immunol. 177 2006 362 371 (Pubitemid 43939148)
52. J.L. Teeling Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas Blood 104 2004 1793 1800 (Pubitemid 39202289)
53. A.W. Pawluczkowycz Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX J. Immunol. 183 2009 749 758
54. D.M. Goldenberg Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects Leuk. Lymphoma 51 2010 747 755
55. K. Tobinai Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma Cancer Sci. 102 2011 432 438
56. A. Forero-Torres A Phase 1 study of AME-133v (LY2469298) an Fc-engineered humanized monoclonal antibody in FcγRIIIa-genotyped patients with previously treated follicular lymphoma Clin. Cancer Res. 18 2012 1395 1403
57. S. Baritaki The anti-CD20 mAb LFB-R603 interrupts the dysregulated NF-(B/Snail/RKIP/PTEN resistance loop in B-NHL cells: role in sensitization to TRAIL apoptosis Int. J. Oncol. 38 2011 1683 1694
58. S. Boehrer Cytotoxic effects of the trifunctional bispecific antibody FBTA05 in ex vivo cells of chronic lymphocytic leukaemia depend on immune-mediated mechanism Anticancer Drugs 22 2011 519 530
59. E. Mössner Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity Blood 115 2010 4393 4402
60. S. Dalle Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101 Mol. Cancer Ther. 10 2011 178 185
61. L.A. Sullivan, and R.A. Brekken The VEGF family in cancer and antibody-based strategies for their inhibition MAbs 2 2010 165 175
62. J.L. Spratlin Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 J. Clin. Oncol. 28 2010 780 787
63. J.D. Schwartz Vascular endothelial growth factor receptor-1 in human cancer: concise review and rationale for development of IMC-18F1 (human antibody targeting vascular endothelial growth factor receptor-1) Cancer 116 Suppl. 2010 1027 1032
64. K. Persaud Involvement of the VEGF receptor 3 in tubular morphogenesis demonstrated with a human anti-human VEGFR-3 monoclonal antibody that antagonizes receptor activation by VEGF-C J. Cell Sci. 117 2004 2745 2756 (Pubitemid 38997257)
65. Z. Hanaizi The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Human Use Eur. J. Cancer 48 2012 237 242
66. K.C. Kaehler Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management Semin. Oncol. 37 2010 485 498
67. A. Ribas Clinical development of the anti-CTLA-4 antibody tremelimumab Semin. Oncol. 37 2010 450 454
68. D.S. Vinay, and B.S. Kwon 4-1BB signaling beyond T cells Cell. Mol. Immunol. 8 2011 281 284
69. T.S. Fisher Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity Cancer Immunol. Immunother. 2012 10.1007/s00262-012-1237-1
70. A. Molckovsky, and L.L. Siu First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting J. Hematol. Oncol. 1 2008 20
71. D.M. Benson Jr. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect Blood 118 2011 6387 6391
72. M. Saresella The PD-1/PD-L1 pathway in human pathology Curr. Mol. Med. 12 2012 259 267
73. J.R. Brahmer Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates J. Clin. Oncol. 28 2010 3167 3175
74. R. Berger Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies Clin. Cancer Res. 14 2008 3044 3051
75. D. Chelius Structural and functional characterization of the trifunctional antibody catumaxomab MAbs 2 2010 309 319
76. C. Haas Mode of cytotoxic action of T cell-engaging BiTE antibody MT110 Immunobiology 214 2009 441 453